Granules India Limited
GRANULES · Pharma · NSE
₹767
Current Market Price
Fair Value (DCF)
₹624
Discount to FV
-18.7%
Updated just now
YieldIQ Score
41/100
Piotroski F-Score
4/9
Economic Moat
Narrow
Confidence
51%
ROE
11.7%
Debt/Equity
0.30
WACC
10.5%
Market Cap
₹19,013 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
18.1%
Return on capital employed
EV / EBITDA
13.4×
Enterprise multiple
Debt / EBITDA
1.7×
Leverage vs earnings
Interest Coverage
11.9×
EBIT covers interest
Current Ratio
1.56×
Short-term liquidity
Asset Turnover
—
Revenue per ₹ of assets
Revenue CAGR (3Y)
4.2%
3-year revenue growth
Revenue CAGR (5Y)
6.2%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹767.3
Bear case
Discount -105.5%
Base case
Discount -23.0%
Bull case
Discount +10.5%
Ratio Trends
GRANULES · last 9 annual periods
ROE
11.7%
ROCE
18.1%
Operating Margin
—
Debt / Equity
0.30×
PE
25.8×
EV / EBITDA
13.4×
Historical Financials
GRANULES · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹3765 Cr | ₹4496 Cr | ₹4490 Cr | ₹4456 Cr | ₹5339 Cr | +9.1% |
| EBITDA | ₹728 Cr | ₹907 Cr | ₹826 Cr | ₹989 Cr | ₹1195 Cr | +13.2% |
| EBIT | ₹581 Cr | ₹743 Cr | ₹653 Cr | — | — | +3.0% |
| PAT | ₹413 Cr | ₹517 Cr | ₹405 Cr | ₹502 Cr | ₹595 Cr | +9.6% |
| EPS (diluted) | ₹16.60 | ₹21.00 | ₹16.72 | — | — | +0.2% |
| CFO | ₹332 Cr | ₹739 Cr | ₹439 Cr | ₹867 Cr | ₹793 Cr | +24.3% |
| CapEx | ₹-398 Cr | ₹-411 Cr | ₹-381 Cr | ₹-572 Cr | ₹-558 Cr | — |
| FCF | ₹-65.7 Cr | ₹328 Cr | ₹58.8 Cr | ₹295 Cr | ₹235 Cr | — |
| Total Assets | ₹4513 Cr | ₹4905 Cr | ₹5521 Cr | ₹6253 Cr | ₹7720 Cr | +14.4% |
| Total Debt | ₹1106 Cr | ₹1136 Cr | ₹1315 Cr | ₹1455 Cr | ₹1512 Cr | +8.1% |
| Shareholders' Equity | ₹2587 Cr | ₹2835 Cr | ₹3226 Cr | ₹3716 Cr | ₹5085 Cr | +18.4% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
GRANULES vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 APLLTD Alembic Pharmaceuticals Limited | -21.0% | 41 | Near Fair Value | 11.9% | 19.3× |
 COHANCE Cohance Lifesciences Limited | -83.4% | 22 | Data Limited | 4.6% | — |
 JUBLPHARMA Jubilant Pharmova Limited | -24.1% | 46 | Near Fair Value | 5.6% | 32.5× |
 NEULANDLAB NEULANDLAB | — | — | Pending | 19.4% | — |
 PPLPHARMA PPLPHARMA | — | — | Pending | 1.1% | — |
Click a ticker to view its fair-value analysis.
Dividend History
29 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹6.75/sh
Last payout
2025-07-31
₹1.50
Peak payout
₹1.50
Trailing yield
0.20%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Granules India Limited (GRANULES.NS) trades at 767.30 vs a model fair value of 623.72, a gap of -18.7%. Piotroski F-score: 4/9. Moat labe...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of GRANULES →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for GRANULES →
Compare
Head-to-head with peers
Compare GRANULES side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse GRANULESNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.